Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
Astrazeneca plc has provided data for their CD22-targeting antibody-drug conjugate (ADC) AZD-4512 under development for the treatment of B-cell malignancies, which still have significant rates of disease resistance and relapse, as well as treatment-related toxicities.
Shanghai Best-Link Bioscience LLC has described polymer-drug conjugates comprising a polymer covalently linked to a cytotoxic drug through a linker and its nanoparticles reported to be useful for the treatment of cancer.
Chengdu Kangnuoxing Biopharma Inc. and Keymed Biosciences Co. Ltd. have identified antibody-drug conjugates comprising antibodies targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA; CD66e) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has disclosed antibody-drug conjugates consisting of antibodies covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Molecules that specifically bind to tumor-associated antigens (TAAs) are crucial for the diagnosis and therapy of cancer. In a recent publication in Molecular Therapy: Oncology, researchers from Université de Nantes presented a novel tailored-made affitin for targeting human mesothelin (hMSLN), which is a TAA overexpressed in many solid cancers and targeted by several experimental drugs.
Amphista Therapeutics Ltd. has developed and presented data for AMX-883, a novel orally bioavailable bromodomain-containing protein 9 (BRD9) degradation inducer for acute myeloid leukemia (AML)
treatment.
Immuse Therapeutics Inc. has described heterocyclic compounds acting as leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer.
Nikang Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a cyclin-dependent kinase 2 (CDK2)- and/or CDK4-targeting moiety through a linker reported to be useful for the treatment of cancer.
RSS
